Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM, Krasin M, Link MP, Donaldson SS, Billups C, Merchant TE, Kun L, Billet AL, Kaste S, Tarbell NJ, Howard S, Friedmann AM, Hurwitz CA, Young JA, Marcus KC, Rai S, Cowan T, Weinstein HJ.
Hudson MM, et al.
J Clin Oncol. 2004 Nov 15;22(22):4541-50. doi: 10.1200/JCO.2004.02.139.
J Clin Oncol. 2004.
PMID: 15542805
Clinical Trial.